Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at ...

A first-of-its-kind vaccine against the vomit bug norovirus is being trialled in the UK, using the same tech employed in the ...

The U.S. FDA has approved Pfizer's respiratory syncytial virus vaccine Abrysvo for individuals 18 to 59 years old that are at ...

New COVID-19 strains are emerging and with it the need for updated vaccines to protect people from the virus. So how do ...

Overall, around 25,000 people are expected to be recruited globally. The vaccine has been engineered to combat three strains ...

He said: “The UK is leading the way to develop a world-first vaccine for this vomiting bug, starting with this innovative ...

A vaccine is to be trialled on thousands of people to find out if it could protect against norovirus - a stomach bug that ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

Study reveals single-chain mRNA vaccines confer 100% protection against lethal mpox challenge in mice, marking a significant ...

The influenza (flu) virus affects millions of Americans each fall, winter and early spring, causing doctor visits, ...

Revaccination at 12 months with the investigational respiratory syncytial virus (RSV) vaccine mRNA-1345 is well tolerated and supported for eligible older adults, according to study results presented ...

A multi-state study, published in The Lancet, is one of the first real world data analyses of the effectiveness of the RSV -- ...